Cyprus receives imported cannabis oils for approved patients

Medical-cannabis supplier Panaxia announced its first delivery to Cyprus on 25 March 2021. The shipment followed a government order for cannabis oils, with products intended for distribution through pharmacies to approved patients.

The government selected two oil concentrations

Panaxia had announced the agreement on 3 February. It said talks with the government had resulted in a confirmed order and import permits for two concentrations of its Panaxir cannabis oils.

The company described the products as manufactured to European pharmaceutical quality standards. Its announcement identified Cyprus’s government as the purchaser and described a market centred on approved medical use.

The March delivery report followed checks by the Israeli Health Ministry and customs authorities. It recorded a supplier moving from an order and permits to an announced shipment.

Patients already had a restricted approval route

Cyprus had announced cannabis-oil access for advanced cancer in 2017. An official explanation described individual ministerial approval, a treating doctor’s prescription and collection through a designated chemist.

The 2021 shipment fitted into that medical supply history. The government could purchase imported products and arrange their distribution, while patients still depended on the relevant clinical and official permissions.

For someone seeking treatment, the significant development was the documented arrival of products through an authorised supplier and purchaser.

Domestic production rules had been published earlier

The 2019 regulations created a separate licensing system for medical-cannabis producers. They addressed premises, staff, security, quality testing, record keeping and trade.

They also established rules for pharmacy preparations and prescriptions, including separate approval for patients under eighteen. The rules excluded smoking as a prescribed method of administration.

In its February statement, Panaxia described that production framework as awaiting implementation. The imported-oil agreement supplied a route to products while the domestic framework developed.

Patients relied on an authorised supply chain

Cyprus’s drug law prohibits unauthorised imports of controlled drugs while allowing permissions through regulations. The import permits announced in the agreement were therefore part of the legal route from manufacturer to patient.

The delivery report described oils purchased by the government for distribution through pharmacies to approved patients. Access depended on those supply arrangements as well as the required clinical and official permissions.

Medical production and industrial-hemp farming followed separate licensing rules in Cyprus, alongside the continuing criminal restrictions on ordinary cannabis possession, growing and supply.^{[1][2][3][4][5]}